Literature DB >> 25143775

GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series).

Parvaneh Karimzadeh1, Narjes Jafari2, Habibeh Nejad Biglari2, Sayena Jabbeh Dari2, Farzad Ahmad Abadi3, Mohammad-Reza Alaee4, Hamid Nemati2, Sasan Saket2, Seyed Hasan Tonekaboni1, Mohammad-Mahdi Taghdiri1, Mohammad Ghofrani1.   

Abstract

OBJECTIVE: GM2-Gangliosidosis disease is a rare autosomal recessive genetic disorder that includes two disorders (Tay-Sachs and Sandhoff disease).These disorders cause a progressive deterioration of nerve cells and inherited deficiency in creating hexosaminidases A, B, and AB. MATERIALS &
METHODS: Patients who were diagnosed withGM2-Gangliosidosis in the Neurology Department of Mofid Children's Hospital in Tehran, Iran from October 2009 to February 2014were included in our study. The disorder was confirmed by neurometabolic and enzyme level detection of hexosaminidases A, B, and AB in reference to Wagnester Laboratory in Germany. We assessed age, gender, past medical history, developmental status, clinical manifestations, and neuroimaging findings of 9 patients with Sandhoff disease and 9 with Tay Sachs disease.
RESULTS: 83% of our patients were the offspring of consanguineous marriages. All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression and 22% had seizures. The patients with Sandhoff and Tay Sachs disease were followed for approximately 5 years and the follow-up showed all patients were bedridden or had expired due to refractory seizures, pneumonia aspiration, or swallowing disorders. Neuro-imaging findings included bilateral thalamic involvement, brain atrophy, and hypo myelination in near half of our patients (48%).
CONCLUSION: According to the results of this study, we suggest that cherry-red spots, hyperacusis, refractory seizures, and relative parents in children with developmental delay and/or regression should be considered for assessment of GM2-Gangliosidosis disease.

Entities:  

Keywords:  Genetic disorders; Neurometabolic disorders; Sandhoff disease; Tay Sachs disease

Year:  2014        PMID: 25143775      PMCID: PMC4135282     

Source DB:  PubMed          Journal:  Iran J Child Neurol        ISSN: 1735-4668


Introduction

Sandhoff disease is a rare autosomal recessive metabolic disorder that has three clinical subtypes (infantile, juvenile, and adult forms)(1,2).The infantile form presents with progressive neurologic impairment, hyperacusis, hypotonia, and bilateral cherry-red spots in the macular region of the retina and seizures(3).The juvenile form manifests with dementia, cerebellar ataxia, mental retardation, and spinal muscular atrophy(4).The clinical manifestation of the adult form of Sandhoff disease varies widely from spinocerebellar degeneration to motor neuron disorders are often reported(5-8). Tay-Sachs disease (TSD) is a neurodegenerative lysosomal disorder with an autosomal recessive inheritance caused by β-hexosaminidase α-subunit (HEXA) mutations (9). The diagnosis of this disorder is based on hexosaminidases A, B, and AB level detection. Decreased levels of hexosaminidases A and B are seen in patients with Sandhoff but solitarily decreased levels of hexosaminidases A are seen in Tay Sachs disease. In this study, we present 5 years of experience about Sandhoff and Tay Sachs disorder from the Pediatric Neurology Research Center of Mofid Children’s Hospital, Tehran, Iran.

Materials & Methods

A total of 18 cases affected byGM2-gangliosidosis disease were assessed in our study from October 2009 to February 2014 in the Neurology Department of Mofid Children’s Hospital, which is the referral center for neurometabolic diseases in Iran. The diagnosis was performed based on clinical manifestations, neuro-imaging findings, and, finally, laboratory assessment of decreased total hexosaminidase enzyme activity for Tay Sachs and Sandhoff disease from a metabolic laboratory in Germany. The data from patients were collected was age, gender, past medical history, developmental status, general appearance, and clinical neuro-imaging findings. Unfortunately, this disorder is incurable and treatment consists of anticonvulsants to manage seizures, proper nutrition, and rehabilitation. The children’s diet was carefully controlled. The data were analyzed by descriptive methods and no statistical testing was applied. Institutional ethical approval for the conduct of this study was obtained from the Pediatric Neurology Research Center (Shahid Beheshti University of Medical Sciences). All parents signed a written consent for participation in this study.

Results

In our study 18 patients with GM2-Gangliosidosis (9 patients with Sandhoff and 9 with Tay Sachs disease) were included. There were 10 males and 8 females with a mean age at time of presentation of15 months and an average age of18 months. Hospitalization history for 2 patients from maternal preeclampsia and for 4 patients from pneumonia (1 patient) and icter (3 patients). The first and chief complaint in 100% of the patients were neurological disorders, such as developmental delays (6 patients), developmental regression (5 patients), or both (7 patients); and 4 patients complained of simultaneous seizures. During developmental assessment, 66% of patients showed developmental regression. The average age for developmental regression was 15 months and the mean age was 12 months(3 months before admission and detection time).Four patients had a history of recurrent hospitalization because of respiratory and urinary tract infections. Eight patients had central hypo tonicity (decreased tonicity and increased DTR) and5 patients had spasticity.55% of patients had visual disorders and fix-follow did not exist during physical examinations. Nine patients had a history of seizure with the most common form of seizure were tonic-myoclonic seizures. Seven patients had hyperacusis. 55% of patients had a dysmorphic face with protruding forehead, depressed nasal bridge, and hypertelorism. Five patients had blond hair (Fig. 1). One patient had hepatomegaly and another had hepato splenomegaly. Weight in 6 patients was below the 3 percentile and height in 10% of patients was below the 5 percentile. Three patients had microcephaly, seven patients showed macrocephaly, and the remainder had normal head circumferences.83% of patients were the offspring from consanguineous marriages. Four patients had a family history of seizures and mental retardation. No abnormality was observed in other physical examinations (chest and abdomen).Cherry-red spots were seen in 88% of patients (Fig.2). In lab data, three patients had increased levels of AST and ALT.
Fig.1

A 9 -month –boy patient of GM2-gangliosidosis with a dysmorphic face, protruding forehead, and a depressed nasal bridge

Fig. 2

Ophtalmoscopic pattern of 9- month-old boy patient with GM2- gangliosidosis characterized with cherry-red spot in retinal Exam

The neuroimaging data showed that39% of patients had normal neuro-imaging; 22% of patients had bilateral thalamic involvement; 22% had brain atrophy, and 16% of patients showed demyelination delay. (Fig. 3 and 4).
Fig 3

An 11-month-old female patient with GM2-gangliosidosis with bilateral thalamic involvement inT2 sequence of the brain MRI

Fig 4

A 10-month-old male patient with GM2-gangliosidosis with bilateral thalamic involvement in brain imaging

Discussion

Sandhoff disease is the one type ofGM2-gangliosidosis may present with developmental regression within the first 6 months of life (10). Tay-Sachs diseaseis another type of GM2-gangliosidosis well-known inherited disease caused by an accumulation of gangliosidosis in the retina and brain (11). Patients with GM2-Gangliosidosis (9 patients with Sandhoff disease and 9 patients with Tay Sachs disease) were referred to our tertiary center equally. There were no sexual differences. The main chief complaint from all patients for detection time was developmental delay or regression. Seizures were indicated in some cases. Four patients had a history of neonatal hospitalization (icter, infection) and four patients had recurrent hospitalization due to respiratory distress and Urinary Tract Infections (UTI). A 9 -month –boy patient of GM2-gangliosidosis with a dysmorphic face, protruding forehead, and a depressed nasal bridge Ophtalmoscopic pattern of 9- month-old boy patient with GM2- gangliosidosis characterized with cherry-red spot in retinal Exam An 11-month-old female patient with GM2-gangliosidosis with bilateral thalamic involvement inT2 sequence of the brain MRI A 10-month-old male patient with GM2-gangliosidosis with bilateral thalamic involvement in brain imaging 72% of patients had central hypotonicity or spasticity. 39% of patients had hyperacusis; 56% of patients had specific facial features;28% of patients had blonde hair and a sunken nose bridge; and 28% of patients had hypertelorism. 83% of patients were offspring of consanguineous marriages. Therefore, having relative parents is an important factor in GM2-gangliosidosis detection. 22% of our Sandhoff patients showed bilateral thalamic involvement as hyper-signal intensity of white matter in T2 weighted. Yun YM et al reported MRIs that showed low signal intensity at the thalamus and high signal intensity at white matter of brain in T2-weighted(1). These manifestations in the infantile form of Sandhoff disease were caused by an accumulation of calcium due to intracellular storage of GM2-ganglioside(12-13). Kokot W et al made proper diagnoses of Sandoff and Tay Sachs disease in their patients based on an early eye fundus examination and seeing cherry-red spots in the central area(14). 55% of our patients did not have fixfollow on visual examination and cherry-red spots were seen in 88% of patients. The treatment of GM2-gangliosidosis is based on patient complaints such as management of the epileptic seizures and an intervention program for the neurological retardation. Case mortality in the infantile form of this disorder with severe neurological deterioration occurs before the age of 4 (3). Organomegaly was seen in only 2 patients and was not an important segregation criterionto distinguishing Sandhoff from Tay Sachs disease in our study. Likewise, Barness et al. also did not report organomegaly in patients with Sandhoff disease (15). However, Arisoy et al. reported a case of Tay Sachs in a twelve-month-old female patient with macrocephaly, hyperacusis, cherry-red spots, and without organomegaly (16). Ozkara et al. showed that in 11 out of 18 infantile patients with Sandhoff disease, there was no evidence of organomegaly, while the remaining seven had mild organomegaly(17). They also reported that 21% of marriages in their patients were consanguineous (17). Therefore, the lack of organomegaly or macrocephaly in the clinical manifestation of our studied group could not preclude a GM2-gangliosidosis diagnosis. Seven patients had macrocephaly, three patients had microcephaly, and eight patients had a normal head circumference. Therefore, macrocephaly, microcephaly, and normal head circumferences were not considered significant in our assessment. Our patients with GM2-gangliosidosis came to our special center and an exact evaluation was done. A high frequency of consanguineous marriage between the patients’ parents must be considered remarkable. In these autosomal recessive disorders, because there is no curative therapy, genetic counselling is important and necessary to prevent the burden of GM2-gangliosidosis as a neuro-metabolic disorder. In conclusions, the first and chief complaint in 100% of the patients were neurological disorders. 83% of patients were offspring of consanguineous marriages and cherry-red spots were seen in 88% of patients. Therefore, cherry-red spots, hyperacusis, refractory seizures, and relative parents in patients with developmental delay or regression are the most important factors in the diagnosis of suspected patients. These factors must be considered as assessment for GM2-gangliosidosis disease.
  16 in total

Review 1.  Sandhoff disease--a case report of 3 siblings and a review of potential therapies.

Authors:  S K Tay; P S Low; H T Ong; K Y Loke
Journal:  Ann Acad Med Singapore       Date:  2000-07       Impact factor: 2.473

2.  A 7-year old white-male boy with progressive neurological deterioration.

Authors:  L A Barness; K Henry; P Kling; R Laxova; M Kaback; E Gilbert-Barness
Journal:  Am J Med Genet       Date:  1991-09-01

3.  MRI in a case of Sandhoff's disease.

Authors:  K Hittmair; D Wimberger; G Bernert; R Mallek; E G Schindler
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

Review 4.  Corneal changes in Tay-Sachs disease.

Authors:  M Ghosh; W S Hunter; C Wedge
Journal:  Can J Ophthalmol       Date:  1990-06       Impact factor: 1.882

5.  Tay-Sachs disease in an Arab family due to c.78G>A HEXA nonsense mutation encoding a p.W26X early truncation enzyme peptide.

Authors:  Alireza Haghighi; Amira Masri; Ruth Kornreich; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

6.  Sandhoff disease in the Turkish population.

Authors:  H A Ozkara; M Topçu; Y Renda
Journal:  Brain Dev       Date:  1997-11       Impact factor: 1.961

7.  Molecular heterogeneity in the infantile and juvenile forms of Sandhoff disease (O-variant GM2 gangliosidosis).

Authors:  B F O'Dowd; M H Klavins; H F Willard; R Gravel; J A Lowden; D J Mahuran
Journal:  J Biol Chem       Date:  1986-09-25       Impact factor: 5.157

8.  [Sandhoff's and Tay-Sachs disease--based on our own cases].

Authors:  Witold Kokot; Krystyna Raczyńska; Jarosława Krajka-Lauer; Barbara Iwaszkiewicz-Bilikiewicz; Jolanta Wierzba
Journal:  Klin Oczna       Date:  2004

9.  Spinocerebellar degeneration: hexosaminidase A and B deficiency in two adult sisters.

Authors:  J G Oonk; H J van der Helm; J J Martin
Journal:  Neurology       Date:  1979-03       Impact factor: 9.910

10.  Tay-Sachs disease: a case report.

Authors:  A E Arisoy; S Ozden; G Ciliv; I Ozalp
Journal:  Turk J Pediatr       Date:  1995 Jan-Mar       Impact factor: 0.552

View more
  12 in total

1.  Clinical and Laboratory Profile of Gangliosidosis from Southern Part of India.

Authors:  Vykuntaraju K Gowda; Priya Gupta; Narmadham K Bharathi; Maya Bhat; Sanjay K Shivappa; Naveen Benakappa
Journal:  J Pediatr Genet       Date:  2020-10-19

2.  Infantile Type Sandhoff Disease with Striking Brain MRI Findings and a Novel Mutation.

Authors:  Mehtap Beker-Acay; Muhsin Elmas; Resit Koken; Ebru Unlu; Aysegul Bukulmez
Journal:  Pol J Radiol       Date:  2016-03-03

3.  Ophthalmologic Findings in Patients with Neuro-metabolic Disorders.

Authors:  Narjes Jafari; Karl Golnik; Mansoor Shahriari; Parvaneh Karimzadeh; Sayena Jabbehdari
Journal:  J Ophthalmic Vis Res       Date:  2018 Jan-Mar

Review 4.  Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.

Authors:  Fedah E Mohamed; Lihadh Al-Gazali; Fatma Al-Jasmi; Bassam R Ali
Journal:  Front Pharmacol       Date:  2017-07-07       Impact factor: 5.810

5.  Sandhoff Disease without Hepatosplenomegaly Due to Hexosaminidase B Gene Mutation.

Authors:  Vykuntaraju K Gowda; Raghavendraswami Amoghimath; Varun M Srinivasan; Maya Bhat
Journal:  J Pediatr Neurosci       Date:  2017 Jan-Mar

Review 6.  Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy.

Authors:  Renato Santos; Olga Amaral
Journal:  Int J Mol Sci       Date:  2019-11-24       Impact factor: 5.923

Review 7.  Approach to neurometabolic diseases from a pediatric neurological point of view.

Authors:  Parvaneh Karimzadeh
Journal:  Iran J Child Neurol       Date:  2015

8.  Neurometabolic Diagnosis in Children who referred as Neurodevelopmental Delay (A Practical Criteria, in Iranian Pediatric Patients).

Authors:  Parvaneh Karimzadeh; Narjes Jafari; Habibeh Nejad Biglari; Sayena Jabbehdari; Simin Khayat Zadeh; Farzad Ahmad Abadi; Azra Lotfi
Journal:  Iran J Child Neurol       Date:  2016

9.  Clinical presentation and outcome in infantile Sandhoff disease: a case series of 25 patients from Iranian neurometabolic bioregistry with five novel mutations.

Authors:  Ali Reza Tavasoli; Nima Parvaneh; Mahmoud Reza Ashrafi; Zahra Rezaei; Johannes Zschocke; Parastoo Rostami
Journal:  Orphanet J Rare Dis       Date:  2018-08-03       Impact factor: 4.123

Review 10.  GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.

Authors:  Andrés Felipe Leal; Eliana Benincore-Flórez; Daniela Solano-Galarza; Rafael Guillermo Garzón Jaramillo; Olga Yaneth Echeverri-Peña; Diego A Suarez; Carlos Javier Alméciga-Díaz; Angela Johana Espejo-Mojica
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.